Cancer  /  Future Value

In 2015, more than 1.6 million new cases of cancer are expected to be diagnosed and close to 600,000 people will die from the disease. Thankfully, major breakthroughs are changing how we prevent, treat, and cure cancer. Treatments are becoming increasingly personalized and advances in immuno-oncology, a field that uses the body’s own immune system to fight cancer, are causing a paradigm shift in cancer treatment. Use the navigation below and the search feature to view the data and to narrow down your search.

42 Matching Facts

Search matching Facts:
No results to display
    • FDA approved cancer advances
       
    • Thousands of potential cancer medicines in development
       
    • Estimated Number of Cancer Survivors in the United States From 1975 to 2012  
    • Over the next 10 years, the number of cancer survivors in the U.S. is predicted to grow from 14.5 million to nearly 19 million (9.3 million men and 9.6 million…  
    • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
    • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
    • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
    • A one percent reduction in cancer-related deaths in the U.S. would be worth an estimated $500 billion to society from increased quality of life and increased productivity from longer lives.  
    • A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.  
    • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.  
    • More than half of cancer deaths in the U.S. are due to preventable causes.  
    • Increased use of medical technology, like colonoscopy and sigmoidoscopy for colon cancer screening, could save $178.2 billion between 2010 and 2035.  
    • Pathogens cause around two million cancer cases worldwide each year. Ninety percent of these cases are attributable to Helicobacter pylori (H Pylori), hepatitis B virus (HBV), hepatitis C virus (HCV),…  
    • If the use of recommended colorectal screening increased to 70.5 percent, 1,000 additional lives could be saved each year.  
    • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
    • Medicines in Devlopment for Cancer, 2008  
    • 750 cancer-fighting medicines are currently in development.  
    • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…  
    • Following the current path, the lung cancer incidence rate will increase by 34% between 2003 and 2023. If an alternative path is taken, there will be 18.4% (92,000) fewer lung…  
    • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…  
    • Medicines in Development for Cancer  
    • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
    • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …  
    • According to the Pharmaceutical Research and Manufacturers of America, a radiopharmaceutical currently in development is a synthetic version of a substance derived from scorpions–chlorotoxin. This could be a powerful…  
    • According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine to fight breast cancer is currently in the pipeline. It targets the Bcl-2 protein, which appears to contribute…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor…  
    • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.  
    • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
    • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.  
    • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…  
    • An experimental drug has been found to extend the lives of kidney patients by about 3.5 months–from 7 to just under 11. It has also been shown to delay…  
    • If the 1 million surgical breast biopsies performed annually were instead performed using image-guided needle core biopsy, the total savings could be $1.6 billion a year.  
    • Medical research that resulted in a 1/5 reduction in deaths from cancer would be worth $10 trillion to Americans-double the national debt.  
    • Widespread use of telomerase inhibitors could result in a 50% cure rate and a 25% prolongation of life for 50% of eligible patients with solid tumors.  
    • Widespread use of selective estrogen receptor modulators could result in an approximately 30% decrease in breast cancer.  
    • Widespread use of cancer vaccines could result in a cure of melanoma/renal cell carcinomas and a 25% boost in survival for all other cancers.  
    • A modest 1% reduction in cancer mortality would be worth close to $500 billion. A cure for cancer (if one is feasible) would be worth around $50 trillion.